Adolescent development and SLE

被引:15
作者
Beresford, MW
Davidson, JE [1 ]
机构
[1] Royal Hosp Sick Children, Dept Rheumatol, Glasgow G3 8SJ, Lanark, Scotland
[2] Royal Liverpool Childrens Hosp, Dept Rheumatol, Liverpool L12 2AP, Merseyside, England
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2006年 / 20卷 / 02期
关键词
systemic lupus erythematosus; adolescence; disease activity; outcome;
D O I
10.1016/j.berh.2005.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adolescence is a time of profound biological and psychosocial change. The management of a complex chronic condition such as systemic lupus erythematosus (SLE) during this period is a challenging but rewarding task for the clinician. Early diagnosis and optimal disease control is essential in order to facilitate normal adolescent development and minimize long-term disease sequelae. Current treatment regimens are associated with significant toxicity in young people, and there is a need for new, less toxic regimens. There are currently no controlled therapeutic studies in adolescents with SLE. Those involved in the care of these young people must ensure that they have appropriate access to specialist medical services while ensuring that their specific needs as adolescents in the health-care system are addressed.
引用
收藏
页码:353 / 368
页数:16
相关论文
共 75 条
  • [11] Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis
    Chan, TM
    Tse, KC
    Tang, CSO
    Mok, MY
    Li, FK
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (04): : 1076 - 1084
  • [12] Mycophenolate mofetil for remission induction in severe lupus nephritis
    Cross, J
    Dwomoa, A
    Andrews, P
    Burns, A
    Gordon, C
    Main, J
    Mathieson, P
    O'Donoghue, D
    Jayne, D
    [J]. NEPHRON CLINICAL PRACTICE, 2005, 100 (03): : C92 - C100
  • [13] Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants
    Doria, A
    Rinaldi, S
    Ermani, M
    Salaffi, F
    Iaccarino, L
    Ghirardello, A
    Zampieri, S
    Della Libera, S
    Perini, G
    Todesco, S
    [J]. RHEUMATOLOGY, 2004, 43 (12) : 1580 - 1586
  • [14] Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression - Case report
    Edelbauer, M
    Jungraithmayr, T
    Zimmerhackl, LB
    [J]. PEDIATRIC NEPHROLOGY, 2005, 20 (06) : 811 - 813
  • [15] Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO
  • [16] 2-I
  • [17] Falcini F, 1998, J RHEUMATOL, V25, P583
  • [18] FERRAZ MB, 1994, CLIN EXP RHEUMATOL, V12, P689
  • [19] Systemic lupus erythematosus in three ethnic groups -: XVI.: Association of hydroxychloroquine use with reduced risk of damage accrual
    Fessler, BJ
    Alarcón, GS
    McGwin, G
    Roseman, J
    Bastian, HM
    Friedman, AW
    Baethge, BA
    Vilá, L
    Reveille, JD
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (05): : 1473 - 1480
  • [20] Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology
    Geusens, PP
    de Nijs, RNJ
    Lems, WF
    Laan, RFJM
    Struijs, A
    van Staa, TP
    Bijlsma, JWJ
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (03) : 324 - 325